❌ The myth: A great Product sells itslef, Regulatory Strategy can come later.
Many MedTech manufacturers share the same assumption: the technology works, the clinical need is clear, and regulatory paperwork is just a final admin step. This belief has delayed, derailed, and ended market entry for otherwise strong products.
Regulatory strategy is not a final hurdle. It is a foundational element of product development. Under EU MDR and IVDR, the cost of getting it wrong has never been higher. As a result the three Misconceptions that Cost Manufacturers Time and Money:
“We’ll handle regulatory once the product is ready.”
By the time a product is finalized, the window for meaningful regulatory input has already closed. Classification, intended purpose, clinical evidence strategy, and conformity assessment route all shape design requirements. Regulatory affairs do not follow development; it must lead to it.
Manufacturers who start late under EU MDR regularly discover the same problems. Their technical documentation does not meet current requirements. Clinical data is insufficient for the device’s risk class. Chosen Notified Body has a waiting list measured in months, not weeks.
“It’s just an update,surely that doesn’t require a full review.”
This is one of the most expensive assumptions in MedTech. EU MDR requires manufacturers to assess every change to materials, intended purpose, software, or labeling against defined criteria. As a matter of fact – there is no automatic exemption for incremental changes.
Manufacturers regularly discover mid-process that a seemingly minor modification triggers a full review. This includes an updated clinical evaluation and potentially new PMCF requirements. Failing to plan this from the outset is not an oversight; furthermore it is a risk management failure.
“We’ll find a Notified Body when we need one.”
The number of Notified Bodies designated under EU MDR remains limited. Capacity constraints are real and well-documented. Selecting the right Notified Body depends on device classification, target markets, product category, and existing certification history.
Engaging too late or choosing a body without relevant expertise creates delays that no internal resources can easily recover. This decision requires expert input, ideally before the conformity assessment process begins.
How EU MDR and IVDR Changed the Game
The bar for placing a medical device on the European market is higher than ever. Clinical evidence standards are more rigorous. Post-market surveillance obligations are more demanding. The UDI system adds traceability requirements across the entire supply chain.
Manufacturers operating under transitional provisions are running out of time. Small and medium-sized companies without dedicated in-house regulatory teams face these requirements for the first time. Those who underestimate them do not face delayed launch. They face no launch at all.
Bottom Line
All things considered: Regulatory expertise is not an overhead cost. It is a prerequisite for market access. Without a defined strategy, even technically excellent products stall at classification, at Notified Body selection, at clinical evidence review, or at post-market surveillance design.
The manufacturers who move fastest through the MDR landscape are not those with the simplest products. They are those who engaged regulatory expertise early, planned their evidence strategy in advance, and understood the rules before the rules became obstacles.